CoChat

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

Open access

The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.

Abstract

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of patients present advanced disease at onset. However, in the last decade, multiple oncogenic driver alterations have been discovered and each of them represents a potential therapeutic target. Although KRAS mutations are the most frequently oncogene aberrations in lung adenocarcinoma patients, effective therapies targeting KRAS have yet to be developed. Moreover, the role of KRAS oncogene in NSCLC remains unclear and its predictive and prognostic impact remains controversial. The study of the underlying biology of KRAS in NSCLC patients could help to determine potential candidates to evaluate novel targeted agents and combinations that may allow a tailored treatment for these patients. The aim of this review is to update the current knowledge about KRAS-mutated lung adenocarcinoma, including a historical overview, the biology of the molecular pathways involved, the clinical relevance of KRAS mutations as a prognostic and predictive marker and the potential therapeutic approaches for a personalized treatment of KRAS-mutated NSCLC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-018-0789-x

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 RAS downstream signaling pathways and potential options for therapeutic intervention in lung adenocarcinoma
Fig. 1 RAS downstream signaling pathways and potential options for therapeutic intervention in lung adenocarcinomaCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 160 references

Cited by

See all 315

Metadata

Authors
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I.
Affiliations
  • Clinica Universidad de Navarra (ES)
  • Centro de Investigación Médica Aplicada (ES)
  • Institut Català d'Oncologia (ES)
  • Antwerp University Hospital (BE)
  • Navarre Institute of Health Research (ES)
Venue
Molecular Cancer
Published
2018-02-19
Volume
17
Issue
1
Pages
33-33
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2795913084
Cited by
301
References
158
Citations by year
2026: 11 · 2025: 18 · 2024: 25 · 2023: 31 · 2022: 39 · 2021: 62 · 2020: 64 · 2019: 37 · 2018: 13
FWCI
7.84
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
Funders
  • Ministerio de Educación, Gobierno de España (FPU15/00173)
  • Instituto de Salud Carlos III (SAF2013-46423-R, PI11/00976, PI15/02223)
  • FP7 People: Marie-Curie Actions (618312 KRASmiR FP7-PEOPLE-2013-CIG)
  • Worldwide Cancer Research (16-0224)
  • RTICC (RD12/0036/0040)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
KRAS mutation, non-small cell lung cancer, lung adenocarcinoma, KRAS-targeted therapy, prognostic factors, predictive biomarkers, molecular pathways, personalized treatment, KRAS inhibitors
MeSH terms
Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Genes, ras

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. https://app.cochat.ai/papers/10.1186/s12943-018-0789-x
The paper
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018). KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Molecular Cancer. https://doi.org/10.1186/s12943-018-0789-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.